---
title: "Darzalex (daratumumab) in multiple myeloma: Drug interactions questions"
description: "Drug interactions questions on Darzalex (daratumumab) in multiple myeloma, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Questions: What drug interactions are listed for Darzalex? 1 question quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/darzalex--multiple-myeloma/drug-interactions"
published: "2026-11-12T22:05:36-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Darzalex (daratumumab) in multiple myeloma: Drug interactions questions

Manufacturer: Janssen Biotech, Inc.  
Prescribing information: [Darzalex](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX-pi.pdf), [Darzalex Faspro](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf)

Questions that apply to every indication of Darzalex are on [Darzalex (daratumumab), all indications](https://www.evicenter.com/medical-information/darzalex).

## Drug interactions

<a id="darzalex-drug-interactions"></a>

### What drug interactions are listed for Darzalex?

> “7	
> DRUG INTERACTIONS
> 7.1	 Effects of Daratumumab on Laboratory Tests
> 8	
> USE IN SPECIFIC POPULATIONS”

Source: [DARZALEX: DARZALEX®, page 1, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX-pi.pdf#page=1)

> “7	
> DRUG INTERACTIONS
> 7.1	 Effects of Daratumumab on Laboratory Tests
> Interference with Indirect Antiglobulin Tests (Indirect Coombs Test)
> Daratumumab binds to CD38 on RBCs and interferes with compatibility testing, 
> including antibody screening and cross matching.”

Source: [DARZALEX: DARZALEX®, page 9, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX-pi.pdf#page=9)

> “Interference with Serum Protein Electrophoresis and Immunofixation Tests
> Daratumumab may be detected on serum protein electrophoresis (SPE) 
> and immunofixation (IFE) assays used for monitoring disease monoclonal 
> immunoglobulins (M protein).”

Source: [DARZALEX: DARZALEX®, page 10, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX-pi.pdf#page=10)

Note: The passages are from the DARZALEX (intravenous) Prescribing Information. The first is its contents entry: section 7 (Drug Interactions) consists of subsection 7.1, Effects of Daratumumab on Laboratory Tests, which covers laboratory test interference only. The others are the two headings of 7.1, each with its first sentence. The DARZALEX FASPRO Prescribing Information has the same contents entry.

## Related pages
- [Medical information: Darzalex (daratumumab): Multiple myeloma](https://www.evicenter.com/medical-information/darzalex--multiple-myeloma)
- [Indication](https://www.evicenter.com/medical-information/darzalex--multiple-myeloma/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/darzalex--multiple-myeloma/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/darzalex--multiple-myeloma/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/darzalex--multiple-myeloma/safety)
- [Dosing and administration](https://www.evicenter.com/medical-information/darzalex--multiple-myeloma/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/darzalex--multiple-myeloma/storage-and-supply)
- [Guidelines](https://www.evicenter.com/medical-information/darzalex--multiple-myeloma/guidelines)
